TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05720065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Randomized double-blind administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline 0,9%
Description: Randomized double-blind administration
Study: NCT06040359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Thriving Mamas programme
Description: Enhanced antenatal course plus usual perinatal care
Study: NCT05551754

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Supplement
Description: Drink a single dose of ketone supplement 25g

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol Beverage
Description: Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%
Study: NCT06040359

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual perinatal care
Study: NCT05853042

Intervention type: DIAGNOSTIC_TEST
Intervention: high-sensitivity cardiac troponin testing
Description: Lithium heparin plasma samples will be measured with Mindray Bio-Medical CL-1200i Chemiluminescence Immunoassay Analyzer.
Study: NCT05985148

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Single-fraction stereotactic radiosurgery (SRS)
Description: Patients will be treated with single-fraction radiation therapy at three dose levels:~70 Gy, 80 Gy, and 90 Gy using image-guided SRS techniques.
Study: NCT06778811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of dexmedetomidine
Description: Intraoperative infusion of 0.3ug/kg/h dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of esketamine
Description: Intraoperative infusion of 0.3mg/kg/h esketamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline control
Description: Intraoperative infusion of equal volumes of saline
Study: NCT06777498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Grain Intervention then fruits and vegetables
Description: TREATMENT 1: Participants will eat whole grains that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when they eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.~TREATMENT 2: Participants will eat fruits and vegetables that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when participants eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Intervention and then whole grains
Description: TREATMENT 1: Participants will eat fruits and vegetables that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when participants eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.~TREATMENT 2: Participants will eat whole grains that add up to the required daily fiber needs. Investigators will provide participants with these products. Participants will follow this intervention for a set period of time. The beginning of the intervention will include a ramp up phase when they eat half of the daily fiber needs to prevent any gastrointestinal distress from suddenly consuming a higher fiber diet than usual.
Study: NCT06778577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular corticosteroid injection (IACI) group
Description: IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suprascapular nerve radiofrequency group (SCNRFT)
Description: SCNRFT is a new choice for treatment of frozen shoulder. The suprascapular nerve is the nerve that is most commonly affected in the condition of a frozen shoulder and it is for this reason that the suprascapular nerve is directly targeted by pulsed radiofrequency treatment. As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to tag the nerve accurately without injury to the nerves or vessels.
Study: NCT06777654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic therapy (RT)
Description: The Bi-Manu-Track (BMT) robot will be provided as the robotic practice. The BMT can be switched from the bilateral practice modules involving bilateral upper limbs to the unilateral module involving the affected upper limb. According to the group assignment, participants will practice the unilateral or bilateral module of BMT training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic therapy (RT)
Description: The Bi-Manu-Track (BMT) robot will be provided as the robotic practice. The BMT can be switched from the bilateral practice modules involving bilateral upper limbs to the unilateral module involving the affected upper limb. According to the group assignment, participants will practice the unilateral or bilateral module of BMT training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT)
Description: The innovative mirror therapy (MT) program will be conducted with computerized mirror visual feedback and the conventional mirror box therapy. The unilateral MT group will practice on the unilateral module, while the bilateral MT group will practice based on the bilateral module. In the unilateral module, the affected hand will be static on the knee. In contrast, during bilateral MT, participants will be asked to do the same movements using the unaffected and affected arms as symmetrically as possible.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT)
Description: The innovative mirror therapy (MT) program will be conducted with computerized mirror visual feedback and the conventional mirror box therapy. The unilateral MT group will practice on the unilateral module, while the bilateral MT group will practice based on the bilateral module. In the unilateral module, the affected hand will be static on the knee. In contrast, during bilateral MT, participants will be asked to do the same movements using the unaffected and affected arms as symmetrically as possible.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dose-matched control intervention
Description: Participants in the control group will receive therapist-mediated rehabilitation per session.
Study: NCT06164093

Intervention type: OTHER
Group type: OTHER
Intervention: RNA sequencing is performed on the remaining LPCs
Description: RNA sequencing is performed on the remaining LPCs previously transplanted back into the patients. And the results are analysed combined with the data from the previous clinical trial. (Please note that patients will not receive cell transplantation again as they have already received the treatment in the previous trial \[NCT03655808\])

Intervention type: OTHER
Group type: OTHER
Intervention: Immunofluorescence staining is performed in the surgically resected lung tissue sections
Description: The aim of this intervention is to detect Krt5 protein expression by staining the surgically resected lung tissue sections. This is done to confirm the presence of a small number of LPCs in the lung tissue of patients with bronchiectasis and to investigate their distribution.
Study: NCT05168046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: program of weekly mindfulness based stress reduction intervention during 2 months and practice during 3 months
Study: NCT05948553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention A Fluoxetine Hydrochloride (HCl)
Description: Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intervention A Placebo
Description: A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
Study: NCT05551754

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Beverage
Description: Subjects will drink about 2 ½ standard alcohol beverages, based on their weight to reach a breath alcohol level of 0.050%
Study: NCT05950945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
Study: NCT04202406

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will receive placebo (starch) 1hour before treatment.
Study: NCT05420311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedDiet Arm
Description: A balanced hypocaloric diet in macronutrients (MedDiet)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KetoDiet Arm
Description: A very low carbohydrate diet (KetoDiet).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IF Arm
Description: An intermittent fasting (IF) approach
Study: NCT06439654

Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care
Description: The study model will utilize the accepted standard of care while implementing key enhancements to proactively reach high-risk patients as early as possible. Wrap around comprehensive care is defined as database screening, outreach, encouraging genetic testing for participants and their family members, and provide ongoing education, medical management (e.g., adherence to FDA-approved medications), routine laboratory testing, specialist referrals, Epic referrals to integrated care support such as pharmacy, nutrition, social work, and community health), and routine follow-up either in-person or using virtual visits. Consultations with pharmacists, nutritionists and genetic counselors or specialists to manage co-morbidities may be requested.
Study: NCT05282030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolebrutinib
Description: Pharmaceutical form: Film-coated tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolebrutinib
Description: Pharmaceutical form: Film-coated tablets Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolebrutinib
Description: Pharmaceutical form: Film-coated tablets Route of administration: oral
Study: NCT05137197

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Predictix Genetics Antidepressant
Description: Predictix Genetics Antidepressant (PGA) is a software tool that is intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with MDD.
Study: NCT06483477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard skin care
Description: From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.
Study: NCT05410106

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PneuX Endotracheal Tube
Description: The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care (Taperguard, Covidien)
Description: Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.
Study: NCT06052722

Intervention type: OTHER
Group type: OTHER
Intervention: Correlation assessment
Description: The relationship between the Premenstrual Syndrome Impact Scale and the Fonseca Anamnestic Index will be examined for individuals with premenstrual syndrome. The relationship between Working Ability, Location, Intensity, Days of Pain, Dysmenorrhea Score and Fonseca Anamnestic Index will be examined for individuals with primary dysmenorrhea.
Study: NCT06483477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard skin care
Description: From the start of radiotherapy, standard skin care has to be performed by the patient. This may vary at the participating centers. At the site in Lübeck, it includes fatty cream with 2-10% urea (fatty cream alone, if patients do not tolerate urea) and, in case of pruritus, addition of mometasone furoate cream. In case of grade ≥2 moist desquamation or grade ≥3 radiation dermatitis, each day antiseptic agents will be administered for wound cleansing followed by administration of silicon or calcium alginate bandage. This treatment will be continued until moist desquamation radiation disappears and radiation dermatitis improves to grade 2. Fatty cream with 2-10% urea is applied to the irradiated skin four times daily. Mometasone furoate cream: In addition to the fatty cream with 2-10% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reminder App
Description: In addition to standard skin care, patients are supported by a Reminder App. The purpose of the app is to remind the patients in an intuitive, unobtrusive and supportive way to perform skin care. By default, patients are reminded four times a day, but they will also be able to define a notification schedule that best suits their personal needs. The patients may postpone each required care procedure for up to 2 hours. With each procedure, the patients are guided through the skin care with simple and self-explanatory illustrations. To increase the patients' motivation, they will additionally earn points for regular and punctual performed care procedures. The patients receive a hand-out including instructions how to properly perform skin care, but they can also find an information page within the application that includes similar instructions.
Study: NCT06116526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab - Discontinuation
Description: Drug injections are discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab - Dose Reduction
Description: The drug is given as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab - Standard Dose
Description: The drug is given as a subcutaneous injection.
Study: NCT05907746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV three times per day starting on day +5 until approximately day +30 (+/- 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg IV three times per day starting on day +5 until approximately day +30 (+/- 2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.02 mg/kg IV daily starting on day +5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.02 mg/kg IV daily starting on day +5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: 50 mg/kg IV daily on days +3 and +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant Cyclophosphamide
Description: 50 mg/kg IV daily on days +3 and +4

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 200cGy on day -1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 200cGy on day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplant
Description: stem cell transplant on day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplant
Description: stem cell transplant on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSP191
Description: Single 0.6 mg/kg IV infusion administered between days -13 and day -10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSP191
Description: Single 0.6 mg/kg IV infusion administered between days -13 and day -10

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV daily on days -6 and -5; for 7/8 Unrelated or Haploidentical Donor, prior to transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 30 minutes daily. For 8/8 Matched Related or Unrelated Donor, fludarabine dose will be on days -4, -3, and -2. For 7/8 Unrelated or Haploidentical Donor, fludarabine dose will be on days -6, -5, -4, -3, and -2.
Study: NCT04408638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive a single dose of intravenous (IV) obinutuzumab pre-treatment 7 days prior to the first dose of glofitamab.
Study: NCT05697705

Intervention type: OTHER
Intervention: ChAdOx1 nCOV-19 vaccine (Vaxzeria)
Description: Used as 2nd booster, 1st booster, or primary series

Intervention type: OTHER
Intervention: ChAdOx1 nCOV-19 vaccine (Vaxzeria)
Description: Used as 2nd booster, 1st booster, or primary series

Intervention type: OTHER
Intervention: BNT162b2 (Pfizer)
Description: Used as 2nd booster, 1st booster, or primary series.

Intervention type: OTHER
Intervention: BNT162b2 (Pfizer)
Description: Used as 2nd booster, 1st booster, or primary series.

Intervention type: OTHER
Intervention: Ad26.COV2.S (Janssen)
Description: Used as 2nd booster, 1st booster, or primary series.

Intervention type: OTHER
Intervention: Ad26.COV2.S (Janssen)
Description: Used as 2nd booster, 1st booster, or primary series.
Study: NCT05397821

Intervention type: PROCEDURE
Intervention: UNC technique
Description: In general, UNC techniques can be divided in being either intravesical or extravesical and refluxing or non-refluxing
Study: NCT05697705

Intervention type: OTHER
Intervention: CoronaVac (Sinovac)
Description: Used as 2nd booster, 1st booster, or primary series.

Intervention type: OTHER
Intervention: CoronaVac (Sinovac)
Description: Used as 2nd booster, 1st booster, or primary series.
Study: NCT05609929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration of omeprazole Single administration of AB-106
Description: Take AB-106 capsule 400 mg orally on an empty stomach in the morning of the first day of the first cycle Take omeprazole magnesium enteric coated tablets 40mg once a day, 30 minutes before breakfast on days 1-4 of the second cycle. On the morning of the fifth day of the second cycle, the subjects will take omeprazole magnesium enteric coated tablets 40 mg, and AB-106 capsules 400 mg after an interval of 1 hour
Study: NCT06062875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be delivered subcutaneously (under the skin) at a dose of 40mg every 2 weeks for a total of 6 doses.
Study: NCT04408638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive IV glofitamab for up to 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxumab
Description: Participants will receive IV rituxumab on Day 1 of each cycle for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed for treatment of cytokine-release syndrome (CRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV gemcitabine prior to oxaliplatin administration for up to 8 cycles.
Study: NCT06146452

Intervention type: OTHER
Intervention: Not
Description: Not
Study: NCT05779995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW001
Description: Inhalation solution
Study: NCT05950945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
Study: NCT05779995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW001
Description: Inhalation solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XW001
Description: Inhalation solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation solution with matched volume

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation solution with matched volume

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation solution with matched volume